Device Trial Radar · NCT04187599
Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)
Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Aug 29, 2019
Primary completion
Nov 30, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- CooperVision International Limited (CVIL)Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- TigerMed
- First posted
- Dec 5, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this post market clinical study is to evaluate the effectiveness and safety of the Paragon CRT®100 Contact Lens.
Conditions
- Myopia
Interventions
Paragon CRT®100 Contact LensDevice
Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- product effectivenessTime frame: 1 month
- uncorrected visual acuityTime frame: At baseline
- uncorrected visual acuityTime frame: 1 day
25 more outcomes with a free account
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Changsha Aier Eye Hospital
Shanghai, China · Recruiting
Eye & ENT Hospital of Fudan University
Shanghai, China · Recruiting
Tianjin Eye Hospital
Tianjin, China · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.